Skip to content

Remimazolam versus propofol for deep sedation during Endoscopic Ultrasound (EUS) procedures. A randomized controlled trial.

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521784-12-00
Acronym
RESPONSE
Enrollment
332
Registered
2025-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric and pancreatic cancer

Brief summary

The primary outcome will be a composite outcome of cardiorespiratory adverse events, Oxygen desaturation, defined as SpO2 < 90% or need to increase the basal oxygen flow., Respiratory depression (desaturation requiring interventions as chin-stiff, bag mask ventilation), Hypotension (mean arterial pressure < 65 mmHg or 20% drop in systolic blood pressure from preprocedural values), Arrhythmia, Tachycardia (HR > 100 beats for minute or a 25% increase from baseline HR) or bradycardia (<50 beats for minute), Need for intervention of anesthesiologist (according to the evaluation of endoscopist).

Detailed description

Evaluation of the quality of sedation, through specific questions (according to patients ‘and endoscopist’s point of view), Time needed to start the procedure, Awakening time, Time spent in recovery room, Time for hospital discharge, Pain at injection, Need for hospital admission, Need to crossover to other arm, Need for advanced respiratory support (tracheal intubation), Need to use additional hypnotic drugs, A cost-effectiveness analysis will be also performed considering costs related to used drugs, employment of personnel and occupation time of endoscopy and recovery room. We will also record all the other drugs used during and after sedation, the time to wake up after sedation (endoscopy room occupancy time) and the time to hospital discharge (recovery room occupancy time).

Interventions

DRUGREMIMAZOLAM
DRUGPROPOFOL

Sponsors

Ospedale San Raffaele S.r.l.
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary outcome will be a composite outcome of cardiorespiratory adverse events, Oxygen desaturation, defined as SpO2 < 90% or need to increase the basal oxygen flow., Respiratory depression (desaturation requiring interventions as chin-stiff, bag mask ventilation), Hypotension (mean arterial pressure < 65 mmHg or 20% drop in systolic blood pressure from preprocedural values), Arrhythmia, Tachycardia (HR > 100 beats for minute or a 25% increase from baseline HR) or bradycardia (<50 beats for minute), Need for intervention of anesthesiologist (according to the evaluation of endoscopist).

Secondary

MeasureTime frame
Evaluation of the quality of sedation, through specific questions (according to patients ‘and endoscopist’s point of view), Time needed to start the procedure, Awakening time, Time spent in recovery room, Time for hospital discharge, Pain at injection, Need for hospital admission, Need to crossover to other arm, Need for advanced respiratory support (tracheal intubation), Need to use additional hypnotic drugs, A cost-effectiveness analysis will be also performed considering costs related to used drugs, employment of personnel and occupation time of endoscopy and recovery room. We will also record all the other drugs used during and after sedation, the time to wake up after sedation (endoscopy room occupancy time) and the time to hospital discharge (recovery room occupancy time).

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026